Insomnia: Causes, Science-Backed Solutions, and When to See a Doctor

Insomnia is the most common sleep disorder on the planet, and it is also the most misunderstood. An estimated 30% of adults experience short-term insomnia in any given year, and roughly 10% meet the clinical criteria for chronic insomnia disorder — defined as difficulty initiating or maintaining sleep at least three nights per week for three months or longer, despite adequate opportunity for sleep, with measurable daytime impairment. Those numbers translate to tens of millions of people lying awake at night, many of whom have tried various remedies, received conflicting advice, and concluded that they are simply bad sleepers. Most of them are wrong. Insomnia is treatable. The challenge is choosing the right treatment.

The 3P Model: Why Insomnia Starts and Why It Stays

The most useful framework for understanding insomnia is the Spielman 3P model, developed by psychologist Arthur Spielman in 1987 and still the foundation of modern insomnia treatment. It identifies three categories of factors that interact to produce and maintain insomnia: predisposing factors, precipitating factors, and perpetuating factors.

Predisposing factors are the traits that make certain people more vulnerable to insomnia. These include genetic predisposition (insomnia runs in families, with heritability estimates around 40%), hyperarousal temperament (people who are naturally more vigilant, anxious, or prone to rumination), and neurobiological differences in the balance between the sleep drive system and the arousal system. Not everyone with predisposing factors develops insomnia, but they are standing closer to the edge.

Precipitating factors are the events that push a vulnerable person over that edge. Job loss, divorce, illness, bereavement, chronic pain, a new baby, travel across time zones, shift work changes — any significant stressor can trigger an acute episode of insomnia. In many cases, the precipitating event is obvious and time-limited, and sleep returns to normal once the stressor resolves. But sometimes it does not, and this is where the third P becomes critical.

Perpetuating factors are the behaviors and thought patterns that keep insomnia going after the precipitating event has passed. They are the reason acute insomnia becomes chronic insomnia, and they are the primary target of cognitive behavioral therapy for insomnia (CBT-I). The most common perpetuating factors include spending excessive time in bed (going to bed early or sleeping in late to "make up" for lost sleep), napping during the day, using the bed for activities other than sleep (reading, scrolling, watching television, worrying), clock-watching during the night, and catastrophizing about the consequences of poor sleep.

What Happens in the Brain During Insomnia

Functional neuroimaging studies have revealed a consistent pattern in patients with chronic insomnia: elevated activity in the brain's arousal networks during the transition from wakefulness to sleep. Specifically, the ascending reticular activating system, the hypothalamic-pituitary-adrenal axis, and the anterior cingulate cortex show higher metabolic activity in insomnia patients compared to good sleepers, both during the pre-sleep period and during non-REM sleep itself. The brain of a person with chronic insomnia is, in a measurable sense, more awake than it should be.

This hyperarousal is not just a nighttime phenomenon. A landmark study by Nofzinger and colleagues published in Sleep (2004) demonstrated that patients with chronic insomnia had elevated whole-brain glucose metabolism during both wakefulness and NREM sleep compared to matched controls. The difference was most pronounced during the transition from waking to sleep, precisely the period when the brain should be rapidly downregulating arousal systems. In insomnia patients, this downregulation is incomplete, and the result is a brain that hovers between sleep and wakefulness rather than making a clean transition.

The hormonal signature of chronic insomnia reflects this hyperarousal. Cortisol levels are elevated across the 24-hour cycle, with the most significant elevation occurring in the evening and early nighttime hours — exactly when cortisol should be declining to its daily nadir. Heart rate variability analysis shows a shift toward sympathetic nervous system dominance, even during periods of quiet rest. Core body temperature, which normally drops by 1–2 degrees Fahrenheit to facilitate sleep onset, shows a blunted decline in many insomnia patients.

Understanding this physiology matters because it explains why simply telling an insomniac to "relax" is unhelpful. Their nervous system is in a state of heightened arousal that is partly habitual and partly biological, and unwinding it requires specific, structured interventions — not willpower.

CBT-I: The Gold Standard Treatment

Cognitive behavioral therapy for insomnia is the recommended first-line treatment for chronic insomnia by the American Academy of Sleep Medicine, the American College of Physicians, and the European Sleep Research Society. It is more effective than medication for long-term management, has no side effects, and produces improvements that persist after treatment ends — something no sleeping pill can claim. Despite this, it remains dramatically underutilized. Most primary care physicians have never received training in CBT-I, and most patients with chronic insomnia have never been offered it.

CBT-I is not talk therapy in the traditional sense. It is a structured, time-limited intervention — typically six to eight sessions delivered weekly — that combines several specific techniques, each targeting a different perpetuating factor.

Sleep restriction therapy is the most potent component and often the most counterintuitive. The patient's time in bed is reduced to match their actual sleep time. If a patient reports sleeping only five hours despite spending eight hours in bed, their initial prescribed time in bed is set at five hours (with a floor of five hours, regardless of reported sleep time). This creates a mild, controlled sleep deprivation that increases sleep drive, consolidates fragmented sleep into a single block, and strengthens the association between bed and sleep. As sleep efficiency improves (the percentage of time in bed spent asleep), time in bed is gradually increased in 15-to-30-minute increments until a balance between sleep duration and efficiency is achieved.

The first week of sleep restriction is often brutal. Patients feel more tired, not less, and they may question whether the treatment is working. This is expected. The temporary worsening is the mechanism. By compressing sleep into a shorter window, the brain is forced to consolidate, and the fragmented, shallow sleep pattern that characterizes chronic insomnia gives way to deeper, more efficient sleep.

Stimulus control therapy restores the association between the bed and sleep. The rules are simple: go to bed only when sleepy; use the bed only for sleep (no reading, screens, or worrying); if unable to fall asleep within approximately 20 minutes, get up and go to another room until sleepy; wake at the same time every morning regardless of how much sleep was obtained; do not nap. These rules dismantle the conditioned arousal response that develops when a person spends hours in bed awake, anxious, and frustrated.

Cognitive restructuring addresses the catastrophic thinking patterns that sustain insomnia. Patients with chronic insomnia tend to overestimate the consequences of poor sleep ("If I don't sleep tonight, I won't be able to function tomorrow"), monitor for sleep-related threats ("I can feel that I'm too awake — this is going to be another bad night"), and engage in effort-based sleep behaviors ("I need to try harder to sleep"). Cognitive restructuring helps patients identify these automatic thoughts, evaluate them against evidence, and replace them with more accurate appraisals.

Relaxation training — including progressive muscle relaxation, diaphragmatic breathing, and body scan meditation — addresses the somatic component of hyperarousal. While relaxation alone is not sufficient to treat chronic insomnia, it complements sleep restriction and stimulus control by reducing the physiological tension that many insomnia patients carry into the bedroom.

Medication: What Works, What Does Not, and What to Watch For

Prescription sleep medications have a role in insomnia treatment, but that role is narrower than most patients and many prescribers realize. The American Academy of Sleep Medicine recommends medication primarily for short-term use (two to four weeks) while CBT-I takes effect, or for patients who have failed or are unable to access CBT-I.

The most commonly prescribed classes include benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon), which bind to the GABA-A receptor and promote sleep onset. Zolpidem (Ambien) is the most frequently prescribed sleeping pill in the United States. It is effective for sleep initiation and has a relatively short half-life (2.5 hours for the immediate-release formulation), but it carries risks of next-morning impairment, complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating), and rebound insomnia upon discontinuation.

Dual orexin receptor antagonists (suvorexant, lemborexant) represent a newer mechanism of action. Instead of broadly suppressing CNS activity like benzodiazepines, they block the wake-promoting orexin system, allowing the brain's natural sleep processes to proceed without artificial sedation. Clinical trials show efficacy for both sleep onset and sleep maintenance with a lower incidence of next-morning grogginess compared to older agents. However, they can cause sleep paralysis and vivid dreams in a subset of patients.

Over-the-counter options deserve scrutiny. Melatonin is effective for circadian rhythm disorders and jet lag but has limited evidence for primary insomnia. Diphenhydramine (Benadryl, ZzzQuil) and doxylamine (Unisom SleepTabs) are first-generation antihistamines that cause drowsiness as a side effect. They are not approved for chronic use, build tolerance within days, impair cognitive performance the following morning, and carry anticholinergic risks that are particularly concerning in older adults (confusion, urinary retention, constipation, increased fall risk). The American Geriatrics Society lists diphenhydramine and doxylamine among medications that should be avoided in adults over 65.

Sleep Hygiene: Necessary But Not Sufficient

Sleep hygiene — the collection of environmental and behavioral recommendations that includes maintaining a consistent schedule, avoiding caffeine and alcohol near bedtime, keeping the bedroom cool and dark, and limiting screen exposure in the evening — is probably the most frequently dispensed sleep advice in medicine. It is also the most overprescribed relative to its efficacy.

Sleep hygiene is not a treatment for insomnia. A systematic review by Irish and colleagues published in the Journal of Clinical Sleep Medicine (2015) found insufficient evidence to recommend sleep hygiene as a standalone intervention for chronic insomnia. Sleep hygiene practices create conditions that support good sleep, but they do not address the conditioned arousal, cognitive distortions, and behavioral patterns that drive chronic insomnia. Handing an insomniac a sleep hygiene pamphlet is like handing a person with a broken leg a pamphlet about good posture. The advice is not wrong; it is just not the treatment.

That said, poor sleep hygiene can undermine effective treatment. A patient undergoing CBT-I who consumes 400 mg of caffeine at 4 PM, scrolls social media in bed for an hour, and sleeps in a room that is 78 degrees is working against their own recovery. Sleep hygiene should be addressed as a foundation, not as a cure. The distinction matters because many patients who have tried "everything" for their insomnia have only tried sleep hygiene advice — and concluded, incorrectly, that nothing works.

Digital CBT-I: Does the App Version Work?

Access to trained CBT-I therapists remains limited. There are fewer than 1,000 board-certified behavioral sleep medicine specialists in the United States, concentrated in academic medical centers and major metropolitan areas. This supply-demand mismatch has driven the development of digital CBT-I programs that deliver the core components of the therapy through smartphone apps and web platforms.

The evidence base for digital CBT-I is encouraging. Somryst (now Pear Therapeutics' proprietary platform) received FDA clearance as a prescription digital therapeutic for chronic insomnia in 2020, based on randomized controlled trial data showing clinically significant improvements in insomnia severity, sleep efficiency, and daytime functioning. Other platforms, including Sleepstation and the CBTI Coach app developed by the U.S. Department of Veterans Affairs, have also demonstrated efficacy in clinical trials, though the effect sizes are generally smaller than those seen with in-person CBT-I delivered by a trained therapist.

Digital CBT-I works best for patients who are self-motivated, comfortable with technology, and able to adhere to the program without therapist accountability. It works less well for patients with comorbid psychiatric conditions (severe depression, PTSD, substance use disorders), who benefit from the clinical judgment and flexibility that a human therapist provides. For many patients, digital CBT-I represents a reasonable first step, with escalation to in-person therapy if the digital program does not produce adequate improvement within six to eight weeks.

When to See a Doctor

Self-management is appropriate for transient insomnia triggered by an identifiable stressor when the symptoms are mild, the duration is short (less than three months), and daytime functioning is not significantly impaired. In these cases, maintaining good sleep hygiene, managing the stressor, and avoiding the perpetuating behaviors described above (especially excessive time in bed and daytime napping) is often sufficient.

Professional evaluation is warranted when insomnia persists for three months or longer, when it causes significant daytime impairment (excessive sleepiness, difficulty concentrating, mood disturbance, reduced work performance), when it co-occurs with symptoms suggestive of another sleep disorder (snoring, witnessed apneas, restless legs, abnormal behaviors during sleep), or when self-directed interventions have failed. A primary care physician can screen for underlying medical and psychiatric conditions, review medications that may be contributing to insomnia, and provide a referral to a sleep specialist or behavioral sleep medicine provider.

Do not wait. The longer chronic insomnia goes untreated, the more deeply entrenched the perpetuating behaviors become, and the harder they are to unlearn. A longitudinal study by Morin and colleagues published in Archives of Internal Medicine (2009) followed adults with insomnia over three years and found that without treatment, chronic insomnia persisted in approximately 70% of cases. The condition does not typically resolve on its own. Treatment works, it is available, and the most important step is asking for it.